The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B‑cell lymphoma patients

Rožman,Samo; Novaković,Srdjan; Grabnar,Iztok; Cerkovnik,Petra; Novaković,Barbara Jezeršek

doi:10.3892/ol.2016.4402

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B‑cell lymphoma patients

Authors:
- Samo Rožman
- Srdjan Novaković
- Iztok Grabnar
- Petra Cerkovnik
- Barbara Jezeršek Novaković
View Affiliations

Affiliations: Department of Pharmacy, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia, Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia, Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, Ljubljana 1000, Slovenia, Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia
Published online on: April 1, 2016 https://doi.org/10.3892/ol.2016.4402
Pages: 3332-3336
Copyright: © Rožman et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rituximab is a monoclonal antibody routinely used in the treatment of B‑cell non‑Hodgkin lymphomas. It mediates antibody‑dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in the FcγR genes have been identified to influence rituximab binding to FcγR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact of FcγRIIa and FcγRIIIa polymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B‑cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted for FcγRIIa‑27, FcγRIIa‑131, FcγRIIIa‑48 and FcγRIIIa‑158 polymorphisms. The median follow‑up time was 29.7 months (range, 9.7‑45.4 months). No significant impact of the genotypes was observed on the treatment response, progression‑free or overall survival of DLBCL patients. There was a non‑significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val at FCγIIIa‑158 compared to Phe carriers. The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients.

View Figures

View References

1	Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, André M, Pfreundschuh M and Dreyling M: ESMO Guidelines Working Group: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7): vii78–vii82. 2012. View Article : Google Scholar : PubMed/NCBI
2	Molina A: A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 59:237–250. 2008. View Article : Google Scholar : PubMed/NCBI
3	Jazirehi AR and Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene. 24:2121–2143. 2005. View Article : Google Scholar : PubMed/NCBI
4	Plosker GL and Figgitt DP: Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 63:803–843. 2003. View Article : Google Scholar : PubMed/NCBI
5	Zhuang Y, Xu W, Shen Y and Li J: Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin' lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 10:347–352. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ravetch JV and Bolland S: IgG Fc receptors. Annu Rev Immunol. 19:275–290. 2001. View Article : Google Scholar : PubMed/NCBI
7	Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, Capel PJ, Aarden LA and van de Winkel JG: On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest. 90:1537–1546. 1992. View Article : Google Scholar : PubMed/NCBI
8	Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE and de Haas M: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 90:1109–1114. 1997.PubMed/NCBI
9	de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJ, Roos D and von dem Borne AE: A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol. 156:2948–2955. 1996.PubMed/NCBI
10	Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, et al: Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 7:286–290. 2007. View Article : Google Scholar : PubMed/NCBI
11	Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA and Capel PJ: A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 147:1338–1343. 1991.PubMed/NCBI
12	Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD and Bittenbring J: The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood. 118:4657–4662. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bordos P, Colombat P and Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 99:754–758. 2002. View Article : Google Scholar : PubMed/NCBI
14	Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimbey E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, et al: Polymorphisms in FcgammaRIIIa (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinaemia. J Clin Oncol. 23:474–481. 2005. View Article : Google Scholar : PubMed/NCBI
15	Weng WK and Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 21:3940–3947. 2003. View Article : Google Scholar : PubMed/NCBI
16	Kim DW, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS and Sohn SK: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 108:2720–2725. 2006. View Article : Google Scholar : PubMed/NCBI
17	Institute of Oncology Ljubljana [Internet]. Ljubljana, Slovenia: Smernice za obravnavo bolnikov z malignimi limfomi. https://www.onko-i.si/uploads/media/Doktrina_limfomi_2015.docAccessed. Feb 11–2015
18	Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 17:12441999.PubMed/NCBI
19	Rohtagi S, Gohil S, Kuniholm MH, Schultz H, Dufaud C, Armour KL, Badri S, Mailliard RB and Pirofski LA: Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. MBio. 4:e00573–e00613. 2013.PubMed/NCBI
20	Mitrovic Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J and Labar B: FCgammaRIIIA and FCgammaRIIa polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica. 92:998–999. 2007. View Article : Google Scholar : PubMed/NCBI
21	Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, Walewski J and Siedlecki JA: FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 52:1604–1606. 2011. View Article : Google Scholar : PubMed/NCBI
22	Váróczy L, Zilahi E, Gyetvai A, Kajtár B, Gergely L, Sipka S and Illés A: Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res. 18:43–48. 2012. View Article : Google Scholar : PubMed/NCBI
23	Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R and Rambaldi A: FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 92:1127–1130. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, et al: Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 18:3478–3486. 2012. View Article : Google Scholar : PubMed/NCBI